Literature DB >> 25859932

MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.

Pooja Panwalkar1, Aliasgar Moiyadi, Atul Goel, Prakash Shetty, Naina Goel, Epari Sridhar, Neelam Shirsat.   

Abstract

Medulloblastoma is the most common and a highly malignant pediatric brain tumor located in the cerebellar region of the brain. Medulloblastomas have recently been shown to consist of four distinct molecular subgroups, viz., WNT, SHH, group 3, and group 4. MiR-206, a miRNA first identified as a myomiR due to its enriched expression in skeletal muscle was found to be expressed specifically in the cerebellum, the site of medulloblastoma occurrence. MiR-206 expression was found to be downregulated in medulloblastomas belonging to all the four molecular subgroups as well as in established medulloblastoma cell lines. Further, the expression of murine homolog of miR-206 was also found to be downregulated in SHH subgroup medulloblastomas from the Smo (+/+) transgenic mice and the Ptch1 (+/-) knockout mice. MiR-206 downregulation in all the four medulloblastoma subgroups suggests tumor-suppressive role for miR-206 in medulloblastoma pathogenesis. The effect of miR-206 expression was analyzed in three established medulloblastoma cell lines, viz., Daoy, D425, and D283 belonging to distinct molecular subgroups. Restoration of miR-206 expression to the levels comparable to those in the normal cerebellum, however, was found to be insufficient to inhibit the growth of established medulloblastoma cell lines. OTX2, an oncogenic miR-206 target, overexpressed in all non-SHH medulloblastomas, is known to inhibit myogenic differentiation of medulloblastoma cells. Overexpression of miR-206 was necessary to downregulate OTX2 expression and inhibit growth of medulloblastoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25859932     DOI: 10.1007/s12031-015-0548-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  24 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

2.  Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway.

Authors:  Amit Gokhale; Ratika Kunder; Atul Goel; Rajiv Sarin; Aliasgar Moiyadi; Asha Shenoy; Chandrasekhar Mamidipally; Santosh Noronha; Sadhana Kannan; Neelam Vishwanath Shirsat
Journal:  J Cancer Res Ther       Date:  2010 Oct-Dec       Impact factor: 1.805

3.  OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.

Authors:  David C Adamson; Qun Shi; Matthew Wortham; Paul A Northcott; Chunhui Di; Christopher G Duncan; Jianjun Li; Roger E McLendon; Darell D Bigner; Michael D Taylor; Hai Yan
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

4.  Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med.

Authors:  H S Friedman; P C Burger; S H Bigner; J Q Trojanowski; C J Wikstrand; E C Halperin; D D Bigner
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

5.  MyoD is a tumor suppressor gene in medulloblastoma.

Authors:  Joyoti Dey; Adrian M Dubuc; Kyle D Pedro; Derek Thirstrup; Brig Mecham; Paul A Northcott; Xiaochong Wu; David Shih; Stephen J Tapscott; Michael LeBlanc; Michael D Taylor; James M Olson
Journal:  Cancer Res       Date:  2013-10-03       Impact factor: 12.701

6.  OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Authors:  Ren-Yuan Bai; Verena Staedtke; Hart G Lidov; Charles G Eberhart; Gregory J Riggins
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

7.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

8.  Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle.

Authors:  Andrie Koutsoulidou; Nikolaos P Mastroyiannopoulos; Denis Furling; James B Uney; Leonidas A Phylactou
Journal:  BMC Dev Biol       Date:  2011-06-07       Impact factor: 1.978

9.  MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats.

Authors:  Line Olsen; Mikkel Klausen; Lone Helboe; Finn Cilius Nielsen; Thomas Werge
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

10.  Downregulation of 14q32 microRNAs in Primary Human Desmoplastic Medulloblastoma.

Authors:  Danielle Ribeiro Lucon; Cristiane de Souza Rocha; Rogerio Bastos Craveiro; Dagmar Dilloo; Izilda A Cardinalli; Denise Pontes Cavalcanti; Simone Dos Santos Aguiar; Claudia Maurer-Morelli; Jose Andres Yunes
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

View more
  13 in total

Review 1.  OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma.

Authors:  Yining Lu; Collin M Labak; Neha Jain; Ian J Purvis; Maheedhara R Guda; Sarah E Bach; Andrew J Tsung; Swapna Asuthkar; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  miR-206 inhibits renal cell cancer growth by targeting GAK.

Authors:  Chao Wei; Shen Wang; Zhang-Qun Ye; Zhi-Qiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

3.  MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1.

Authors:  Xuexia Pan; Zhimin Wang; Bin Wan; Zhenwen Zheng
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

Review 4.  Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.

Authors:  Alti Dayakar; Kumar D Shanmukha; Suresh K Kalangi
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.742

Review 5.  miR miR on the wall, who's the most malignant medulloblastoma miR of them all?

Authors:  Xin Wang; Borja L Holgado; Vijay Ramaswamy; Stephen Mack; Kory Zayne; Marc Remke; Xiaochong Wu; Livia Garzia; Craig Daniels; Anna M Kenney; Michael D Taylor
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

Review 6.  Indian data on central nervous tumors: A summary of published work.

Authors:  Archya Dasgupta; Tejpal Gupta; Rakesh Jalali
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

7.  Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.

Authors:  Kira S Sheinerman; Jon B Toledo; Vladimir G Tsivinsky; David Irwin; Murray Grossman; Daniel Weintraub; Howard I Hurtig; Alice Chen-Plotkin; David A Wolk; Leo F McCluskey; Lauren B Elman; John Q Trojanowski; Samuil R Umansky
Journal:  Alzheimers Res Ther       Date:  2017-11-09       Impact factor: 6.982

8.  Comprehensive analysis of a microRNA expression profile in pediatric medulloblastoma.

Authors:  Junqiang Dai; Qiao Li; Zhitong Bing; Yinian Zhang; Liang Niu; Hang Yin; Guoqiang Yuan; Yawen Pan
Journal:  Mol Med Rep       Date:  2017-04-20       Impact factor: 2.952

9.  miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children.

Authors:  Michela Visani; Gianluca Marucci; Dario de Biase; Felice Giangaspero; Francesca Romana Buttarelli; Alba Ariela Brandes; Enrico Franceschi; Giorgia Acquaviva; Alessia Ciarrocchi; Kerry Jane Rhoden; Giovanni Tallini; Annalisa Pession
Journal:  Diagnostics (Basel)       Date:  2020-04-29

10.  Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.

Authors:  Harish Shrikrishna Bharambe; Raikamal Paul; Pooja Panwalkar; Rakesh Jalali; Epari Sridhar; Tejpal Gupta; Aliasgar Moiyadi; Prakash Shetty; Sadaf Kazi; Akash Deogharkar; Shalaka Masurkar; Kedar Yogi; Ratika Kunder; Nikhil Gadewal; Atul Goel; Naina Goel; Girish Chinnaswamy; Vijay Ramaswamy; Neelam Vishwanath Shirsat
Journal:  Acta Neuropathol Commun       Date:  2019-04-03       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.